Rajeshwari Mahalingham
Neurology with Special Qualifications in Child Neurology · New Brunswick, NJNPI 1477566222
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 91 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by DIXI Medical USA Corp at 32.3% of the total. Reporting peaked in 2023 at $1,091 and has fallen 79.1% since, to $228 in 2025.
Across 91 payments — averaging $28.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- DIXI Medical USA Corp$852
- Sunovion Pharmaceuticals Inc.$296
- SK Life Science, Inc.$246
- UCB, Inc.$152
- Novartis$132
- Neuropace, Inc.$96
- plus $864 from 20 others
Across 50 payments — averaging $4778.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- H. Lundbeck A S$121K
- SK Life Science, Inc.$91K
- Takeda Pharmaceuticals U.S.A., Inc.$19K
- Eisai Inc.$9K
- Novartis$250
What the payments were for
- Food & beverage$2,58098%
- Education$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| DIXI Medical USA Corp | 1 | $852 |
| Sunovion Pharmaceuticals Inc. | 18 | $296 |
| SK Life Science, Inc. | 7 | $246 |
| UCB, Inc. | 4 | $152 |
| Novartis | 9 | $132 |
| Neuropace, Inc. | 1 | $96 |
| Neurelis, Inc. | 5 | $87 |
| Teva Pharmaceuticals USA, Inc. | 6 | $85 |
| Livanova USA, Inc. | 4 | $76 |
| AbbVie | 5 | $71 |
| Acadia Pharmaceuticals Inc | 3 | $60 |
| Pyros Pharmaceuticals, Inc. | 1 | $58 |
| Supernus Pharmaceuticals, Inc. | 4 | $55 |
| Tris Pharma Inc | 4 | $55 |
| Medtronic | 1 | $46 |
| Aucta Pharmaceuticals, Inc. | 3 | $42 |
| Jazz Pharmaceuticals Inc. | 2 | $36 |
| Biocodex, Inc. | 2 | $32 |
| Upsher-smith Laboratories LLC | 2 | $29 |
| Mallinckrodt Enterprises LLC | 2 | $29 |
| Aquestive Therapeutics, Inc. | 2 | $29 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Harmony Biosciences LLC | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Sanofi | 1 | $14 |
How this compares
$2,638 in reported general payments places this provider in the 85th percentile of 69 neurology with special qualifications in child neurology providers in New Jersey.
See all neurology with special qualifications in child neurology providers in New Jersey →
Other neurology with special qualifications in child neurology in New Brunswick
- Carlos LastraNew Brunswick$5K
- Vikram BhiseNew Brunswick$3K
- Janti ChaabanNew Brunswick$495
- Chandrabhaga MiskinNew Brunswick$392
- Anu VenkatNew Brunswick$235
- Andrea RichardsNew Brunswick$180
- Stephanie EnnerNew Brunswick$137
- Amanda SpinnerNew Brunswick$81
- Juliann PaolicchiHackensack$80K
- Trevor DesouzaMorristown$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.